J C Cather|M A Menter - JoVE Visualize

Showing results (11-20 of 23) with videos related to

Pageof 3

Sort By:

Journal of the American Academy of Dermatology|March 5, 1998

Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndromeJ C Cather, C Jackow, J Yegge, et al.

International Journal of Dermatology|March 1, 1996

Psoriasis and pregnancy: hormone and immune system interactionA S Boyd, L F Morris, C M Phillips, et al.

Journal of the American Academy of Dermatology|November 1, 1993

Methotrexate and reproduction in men: case report and recommendationsL F Morris, M J Harrod, M A Menter, et al.

Journal of the American Academy of Dermatology|November 12, 1998

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymomaJ C Cather, A Farmer, C Jackow, et al.

Blood|January 1, 1997

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansionC M Jackow, J C Cather, V Hearne, et al.

Cutis|May 1, 1992

Oral lesions in patients with psoriasis: a controlled studyL F Morris, C M Phillips, W H Binnie, et al.

The British Journal of Dermatology|January 23, 2016

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.

Cutis|November 1, 1988

Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percentR S Medansky, R Bressinck, G W Cole, et al.

The British Journal of Dermatology|April 8, 2021

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.

Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:

Pageof 3

Journal of the American Academy of Dermatology|March 5, 1998

Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndromeJ C Cather, C Jackow, J Yegge, et al.

International Journal of Dermatology|March 1, 1996

Psoriasis and pregnancy: hormone and immune system interactionA S Boyd, L F Morris, C M Phillips, et al.

Journal of the American Academy of Dermatology|November 1, 1993

Methotrexate and reproduction in men: case report and recommendationsL F Morris, M J Harrod, M A Menter, et al.

Journal of the American Academy of Dermatology|November 12, 1998

Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymomaJ C Cather, A Farmer, C Jackow, et al.

Blood|January 1, 1997

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansionC M Jackow, J C Cather, V Hearne, et al.

Cutis|May 1, 1992

Oral lesions in patients with psoriasis: a controlled studyL F Morris, C M Phillips, W H Binnie, et al.

The British Journal of Dermatology|January 23, 2016

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.

Cutis|November 1, 1988

Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percentR S Medansky, R Bressinck, G W Cole, et al.

The British Journal of Dermatology|April 8, 2021

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.

Pageof 3